CTLA4 and myelodysplastic syndrome: In the light of these data, the use of PD-1 and CTLA-4 inhibitors, monoclonal antibodies anti-PD-1 (nivolumab) [160] and anti-CTLA-4 (ipilimumab) [161], was considered in MDS.